OTC : KYKOF

Kyowa Kirin Co., Ltd.

$14.425 USD

$0 (0.0%)

Volume
17
Average Volume
578
Market Capitalization
$7.55B
P/E Ratio
19.06
Dividend Yield
2.52%
Price Target
Year High
$18.00
Year Low
$12.42
Day High
—
Day Low
—
Payout Ratio
$0.45
Current Ratio
$3.18
Company Overview

OTC

Abdul Hafeez Mullick

Drug Manufacturers - General

Healthcare

KYKOF

5161

JP

USD

https://www.kyowakirin.co.jp

81 3 5205 7200

N/A

N/A

Liquidity Metrics

0.02

3.18

2.73

1.73

0.45

Sales & Valuation

$497.26B

2.72

1.56

12.89

205.89

Profitability

$128.18

$67.1B

14.28%

18.27%

8.39%

6.83%

P/E Metrics

19.06

0.44

0.44

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Poll Results

About Kyowa Kirin Co., Ltd. (OTC:KYKOF) Stock

Kyowa Kirin Co., Ltd. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of medicines, with a primary focus on therapeutic areas including oncology, nephrology, central nervous system disorders, and immunological conditions. The company's extensive pharmaceutical portfolio encompasses solutions across its core therapeutic areas. Within oncology, key products include ABSTRAL, a sublingual fentanyl formulation for breakthrough cancer pain management, and LEUNASE, utilized for acute lymphoblastic leukemia. They also offer GRAN, a human colony-stimulating factor, and the G-LASTA/Peglasta/Neulasta range, developed to address chemotherapy-induced febrile neutropenia. Pain management also includes PecFent, a nasal spray, while SANCUSO is available ... to treat chemotherapy-related nausea and vomiting. POTELIGEO, a humanized monoclonal antibody, targets the CC chemokine receptor 4. In nephrology, Kyowa Kirin's offerings feature CONIEL, a calcium channel blocker for hypertension and angina pectoris, along with erythropoiesis stimulating agents like ESPO and NESP. Treatments for secondary hyperparathyroidism include REGPARA and the oral calcimimetics agent ORKEDIA. Crysvita, a recombinant human monoclonal IgG1 antibody, is specifically designed to target fibroblast growth factor 23. For central nervous system disorders, Nouriast/Nourianz acts as an adenosine receptor antagonist in Parkinson's disease. Immunological conditions and allergies are addressed by ALLELOCK, an antihistamine, and LUMICEF, a biological therapy for moderate to severe plaque psoriasis. Additional products include Moventig, a mu-opioid receptor antagonist for opioid-induced constipation, and Romiplate/Nplate, a genetically recombinant protein that stimulates platelet production via thrombopoietin receptors. Beyond its existing portfolio, Kyowa Kirin is actively expanding its pipeline through strategic collaborations. A notable partnership with Amgen Inc. involves the co-development and future commercialization of KHK4083. This Phase 3-ready asset is an anti-OX40 fully human monoclonal antibody intended for the treatment of atopic dermatitis. Tracing its origins back to its incorporation in 1949, the company adopted its current name, Kyowa Kirin Co., Ltd., in June 2019, previously operating as Kyowa Hakko Kirin Co., Ltd. It maintains its headquarters in Tokyo, Japan, and operates as a subsidiary of Kirin Holdings Company, Limited.

The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH

2026-06-23 08:30:00

New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

2026-06-10 08:00:00

New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation

Frequently Asked Questions

What is the current Kyowa Kirin Co., Ltd. (KYKOF) stock price?

Kyowa Kirin Co., Ltd.(OTC:KYKOF) stock price is $14.425 in the last trading session. During the trading session, KYKOF stock reached the peak price of $18 while $12.42 was the lowest point it dropped to. The percentage change in KYKOF stock occurred in the recent session was 0.0% while the dollar amount for the price change in KYKOF stock was $0.

KYKOF's industry and sector of operation?

The OTC listed KYKOF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of KYKOF?

Abdul Hafeez Mullick | President, Chief Executive Officer & Representative Director
Takeyoshi Yamashita | Executive VP, Chief Scientific Officer & Director
Stacey Minton | Global Corporate Communications Head
Naohiko Kubo | Global Finance Head & Accounting Manager
Kazuki Nemoto | Head of Global Legal

How many employees does KYKOF have?

Number of KYKOF employees currently stands at 5161. KYKOF operates from Otemachi Financial City Grand Cube, Tokyo, TY 100-0004, JP.

Link for KYKOF official website?

Official Website of KYKOF is: https://www.kyowakirin.co.jp

How do I contact KYKOF?

KYKOF could be contacted at phone #81 3 5205 7200 and can also be accessed through its website. KYKOF operates from Otemachi Financial City Grand Cube, Tokyo, TY 100-0004, JP.

How many shares of KYKOF are traded daily?

The average number of KYKOF shares traded daily for last 3 months was 578.

What is the market cap of KYKOF currently?

The market value of KYKOF currently stands at $7.55B with its latest stock price at $14.425